Komori
PRISM BioLab (206A) · RiskMitigated

Failure to Register Pending Patents and Constraints Resulting from Third-Party Intellectual Property

First written in FY2024. 3 of 4 entries say "Mitigated", first in FY2025. Latest entry: 2026-05-18.

4entries
3years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024MitigatedFY2025 – 2026-05-182024: 12025: 120252026: 22026
Same theme, other companies
Risk of Losing IP Competitiveness Due to Failure to Obtain Patents, Obsolescence, Inability to Obtain Licenses, and InfringementA theme 109 companies write about · 109 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2020: 4 of 43 companies on the "Worse" side.

14 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 109 companies compared. The sentences above are computed from all 109.
Full recordFilings, disclosures and news, newest first
  2. FY2025MitigatedAnnual report

    「As a result, as of the end of the fiscal year, we had filed or registered 13 patents (10 registered and 3 pending). Going forward, we intend to increase new filings and the registration of filed patents in order to secure intellectual property rights more extensively.」

    The total number of patents remained unchanged at 13, but registered patents increased from 8 to 10, while pending applications decreased from 5 to 3.
  3. FY2024First statedAnnual report

    「As a result, as of the end of the fiscal year, we had filed or registered 13 patents (8 registered and 5 pending). Going forward, we intend to increase new filings and the registration of filed patents in order to secure intellectual property rights more extensively.」

    The company identifies as risks the possibility that patents may not be registered and business constraints arising from third parties' superior intellectual property rights.
Moved together

"Progress in the E7386 Phase II Clinical Trial and Clinical POC" moved the same way as this thread, in the same document, in 2 of its 4 moves.

22★12
  1. ★This thread
  2. 1Progress in the E7386 Phase II Clinical Trial and Clinical POC2×
  3. 2Maintaining multiple in-house drug discovery programs and continuously selecting new targets2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for PRISM BioLab yet. It last moved in the Earnings presentation of 2026-05-18: "Mitigated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.